Media stories about Foundation Medicine (NASDAQ:FMI) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Foundation Medicine earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.0735830954725 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s rankings:

Foundation Medicine (FMI) opened at $64.85 on Friday. The company has a current ratio of 2.24, a quick ratio of 2.03 and a debt-to-equity ratio of 0.47. Foundation Medicine has a fifty-two week low of $22.40 and a fifty-two week high of $75.20. The stock has a market cap of $2,410.80, a price-to-earnings ratio of -14.51 and a beta of -0.03.

A number of research analysts have issued reports on FMI shares. Goldman Sachs Group started coverage on shares of Foundation Medicine in a report on Monday, January 29th. They issued a “neutral” rating and a $73.00 price target for the company. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research cut shares of Foundation Medicine from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $52.25.

In related news, COO Steven J. Kafka sold 5,774 shares of the firm’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $58.57, for a total transaction of $338,183.18. Following the completion of the transaction, the chief operating officer now owns 96,761 shares of the company’s stock, valued at $5,667,291.77. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Evan/ Fa Jones sold 6,500 shares of the firm’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $60.66, for a total transaction of $394,290.00. Following the transaction, the director now directly owns 19,652 shares of the company’s stock, valued at approximately $1,192,090.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 228,717 shares of company stock valued at $14,987,592. 2.70% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Foundation Medicine (FMI) Getting Somewhat Positive Media Coverage, Accern Reports” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/02/10/foundation-medicine-fmi-getting-somewhat-positive-media-coverage-accern-reports.html.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.